These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19822821)

  • 1. Can the Food and Drug Administration ensure that our pharmaceuticals are safely manufactured?
    Hubbard WK
    Arch Intern Med; 2009 Oct; 169(18):1655-6. PubMed ID: 19822821
    [No Abstract]   [Full Text] [Related]  

  • 2. Trying times at the FDA--the challenge of ensuring the safety of imported pharmaceuticals.
    Schweitzer SO
    N Engl J Med; 2008 Apr; 358(17):1773-7. PubMed ID: 18434648
    [No Abstract]   [Full Text] [Related]  

  • 3. Playing "kick the FDA"--risk-free to players but hazardous to public health.
    Wood AJ
    N Engl J Med; 2008 Apr; 358(17):1774-5. PubMed ID: 18434649
    [No Abstract]   [Full Text] [Related]  

  • 4. Criminal conviction for distribution of a drug not approved by the FDA.
    Brushwood DB
    Am J Hosp Pharm; 1991 Apr; 48(4):747-9. PubMed ID: 2042679
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 6. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM
    Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
    [No Abstract]   [Full Text] [Related]  

  • 7. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
    Schwemer WL; Lynch MA
    J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
    [No Abstract]   [Full Text] [Related]  

  • 8. The FDA and congress: differing agendas?
    Lipman AG
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):116-7. PubMed ID: 20504131
    [No Abstract]   [Full Text] [Related]  

  • 9. Transparency initiative moves ahead despite official's departure.
    Schubert C
    Nat Med; 2011 Feb; 17(2):141. PubMed ID: 21297591
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulatory science and the role of the regulator in biomedical innovation.
    Honig PK; Huang SM
    Clin Pharmacol Ther; 2012 Mar; 91(3):347-52. PubMed ID: 22343804
    [No Abstract]   [Full Text] [Related]  

  • 11. Suppressed study raises spectre of flawed drug regulation in US.
    Marris E
    Nature; 2004 Dec; 432(7017):537. PubMed ID: 15577867
    [No Abstract]   [Full Text] [Related]  

  • 12. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
    Teufel AT
    J Contemp Health Law Policy; 2006; 22(2):383-408. PubMed ID: 17117702
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceutical product integrity: can the FDA assure quality?
    Bernstein I
    Manag Care; 2004 Mar; 13(3 Suppl):30-3. PubMed ID: 15074168
    [No Abstract]   [Full Text] [Related]  

  • 14. U.S. Food and Drug Administration requests for input on HR 3204 enactment: the Drug Quality and Security Act of 2013.
    Miller DG
    Int J Pharm Compd; 2014; 18(1):35-6. PubMed ID: 24881338
    [No Abstract]   [Full Text] [Related]  

  • 15. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 16. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
    Willis KD
    Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
    [No Abstract]   [Full Text] [Related]  

  • 17. The Food and Drug Administration and its problems.
    Iglehart JK
    N Engl J Med; 1991 Jul; 325(3):217-20. PubMed ID: 2052069
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug safety special: the safety catch.
    Wadman M
    Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
    [No Abstract]   [Full Text] [Related]  

  • 19. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 20. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH
    J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.